<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Overweight, obesity, and weight reduction in hypertension
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Overweight, obesity, and weight reduction in hypertension
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Overweight, obesity, and weight reduction in hypertension
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Lawrence J Appel, MD, MPH
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            F Xavier Pi-Sunyer, MD, MPH
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            George L Bakris, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sara Swenson, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Karen Law, MD, FACP
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Oct 19, 2021.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Excess weight typically raises blood pressure, and weight loss usually lowers blood pressure [
         <a href="#rid1">
          1
         </a>
         ]. In addition to increasing the risk of hypertension, overweight and obesity increase cardiovascular risk through adverse effects on lipids, insulin resistance, and other cardiometabolic processes. Other adverse effects of overweight and obesity include higher risks of cancer, chronic kidney disease, osteoarthritis, other comorbidities and increased all-cause mortality [
         <a href="#rid2">
          2
         </a>
         ]. The relationship between adiposity and these outcomes is direct and progressive (ie, risk increases as adiposity increases) [
         <a href="#rid3">
          3
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5370.html" rel="external">
          "Overweight and obesity in adults: Health consequences"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          EFFECTS OF ADIPOSITY ON BLOOD PRESSURE
         </span>
        </p>
        <p class="headingAnchor" id="H3006690009">
         <span class="h2">
          Epidemiology
         </span>
         <span class="headingEndMark">
          —
         </span>
         Increased adiposity, whether assessed as higher body mass index (BMI), higher weight, or larger waist circumference, is strongly associated with higher blood pressure and development of hypertension [
         <a href="#rid4">
          4-7
         </a>
         ]. In the Nurses' Health Study [
         <a href="#rid4">
          4
         </a>
         ], for example, BMI at age 18 years and at midlife was positively associated with the occurrence of hypertension  (
         <a class="graphic graphic_figure graphicRef76866" href="/z/d/graphic/76866.html" rel="external">
          figure 1
         </a>
         ). Weight gain was also associated with increased risk; the relative risks of hypertension in women who gained 5.0 to 9.9 kg and ≥25.0 kg were 1.7 and 5.2, respectively  (
         <a class="graphic graphic_figure graphicRef52842" href="/z/d/graphic/52842.html" rel="external">
          figure 2
         </a>
         ).
        </p>
        <p>
         It is difficult to determine the fraction of hypertension that can be attributed to overweight and obesity. In the Framingham Heart Study, in which participants who were prospectively followed for up to 44 years [
         <a href="#rid8">
          8
         </a>
         ], it was estimated that excess body weight (including overweight and obesity) accounted for approximately 26 percent of cases of hypertension in men and 28 percent in women. In the Nurses' Health Study, in which women were followed for up to 16 years, the fraction of new hypertension cases attributable to overweight and obesity was 40 percent [
         <a href="#rid6">
          6
         </a>
         ]. Hence, while overweight and obesity increase the risk of hypertension, it is well-recognized that hypertension is commonplace in nonoverweight individuals and that factors other than excess weight raise blood pressure.
        </p>
        <p class="headingAnchor" id="H1132976953">
         <span class="h2">
          Pathogenesis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The rise in blood pressure seen with obesity is initially associated with an elevation in cardiac output and a relatively normal systemic vascular resistance (SVR) [
         <a href="#rid9">
          9
         </a>
         ]. However, normotensive individuals with obesity have the same cardiac output but an SVR that is below that of lean normotensives. Thus, the hemodynamic difference between hypertensive and normotensive people with obesity is an elevation in SVR in hypertensives, a difference similar to hypertensive and normotensive lean subjects [
         <a href="#rid9">
          9
         </a>
         ]. In addition, individuals with obesity may have increased activation of the renin-angiotensin-aldosterone system [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
         These hemodynamic alterations, plus abnormalities in lipid and glucose metabolism, appear to be related to fat distribution, not just total body weight [
         <a href="#rid3">
          3,11
         </a>
         ]. Specifically, the risk of obesity-related abnormalities is greatest in those patients with abdominal (also called "upper body" or "central") obesity.
        </p>
        <p>
         Numerous mechanisms by which overweight and obesity raise blood pressure have been proposed [
         <a href="#rid3">
          3,12,13
         </a>
         ]. It is likely that several mechanisms are operant simultaneously.
        </p>
        <p class="headingAnchor" id="H220804916">
         <span class="h3">
          Renal injury
         </span>
         <span class="headingEndMark">
          —
         </span>
         Increased renal tubular sodium reabsorption impairs pressure natriuresis and plays an important role in initiating obesity-related hypertension [
         <a href="#rid13">
          13
         </a>
         ]. Potential mediators of abnormal kidney function include (1) physical compression of the kidneys by fat in and around the kidneys, (2) activation of the renin-angiotensin-aldosterone system, and (3) increased sympathetic nervous system activity. Increases in systemic blood pressure and glomerular hyperfiltration subsequently lead to renal injury and chronic kidney disease.
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h3">
          Hyperinsulinemia and insulin resistance
         </span>
         <span class="headingEndMark">
          —
         </span>
         There may be a central role for peripheral insulin resistance, leading to impaired glucose tolerance and hyperinsulinemia, in the development of obesity-related hypertension [
         <a href="#rid14">
          14
         </a>
         ]. Hyperinsulinemia might increase blood pressure through increased sympathetic activity [
         <a href="#rid15">
          15
         </a>
         ], volume expansion from increased renal sodium reabsorption [
         <a href="#rid16">
          16
         </a>
         ], endothelial dysfunction [
         <a href="#rid17">
          17
         </a>
         ], upregulation of angiotensin II receptors [
         <a href="#rid17">
          17
         </a>
         ], and decreased cardiac natriuretic peptide [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h3">
          Sleep apnea syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with obesity often have sleep-disordered breathing and sleep apnea, both of which raise blood pressure [
         <a href="#rid18">
          18
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7705.html" rel="external">
          "Obstructive sleep apnea and cardiovascular disease in adults", section on 'Hypertension'
         </a>
         .)
        </p>
        <p>
         The prevalence of sleep apnea is approximately 40 percent in moderately overweight individuals and between 40 and 90 percent in adults with obesity [
         <a href="#rid19">
          19
         </a>
         ]. This contrasts with the prevalence of obstructive sleep apnea in the general population (13 to 30 percent among adult men and 6 to 19 percent among adult women) [
         <a href="#rid20">
          20
         </a>
         ]. In this context, it is likely that sleep apnea contributes to elevated blood pressure in patients who are overweight or obese. Activation of the sympathetic nervous system, enhanced aldosterone levels, and increased levels of endothelin by repeated episodes of hypoxia are thought to be responsible in part for the elevation in blood pressure in this disorder [
         <a href="#rid21">
          21,22
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3862.html" rel="external">
          "Evaluation of secondary hypertension"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h3">
          Leptin-melanocortin pathway
         </span>
         <span class="headingEndMark">
          —
         </span>
         The correlation between the serum concentration of leptin, a protein that signals the brain about the quantity of stored fat, and body fat content in humans is approximately 0.9. This and other observations have led to speculation that, with increasing adiposity, leptin acts as a negative feedback "adipostatic" signal to brain centers controlling energy intake  (
         <a class="graphic graphic_figure graphicRef86697" href="/z/d/graphic/86697.html" rel="external">
          figure 3
         </a>
         ) [
         <a href="#rid23">
          23
         </a>
         ] (see
         <a class="medical medical_review" href="/z/d/html/5378.html" rel="external">
          "Obesity: Genetic contribution and pathophysiology"
         </a>
         ). There is evidence that leptin may have a role in obesity-related hypertension, particularly via increased sympathetic activity [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
         The melanocortin receptor, which is expressed on downstream targets of leptin- and insulin-responsive neurons, is involved in the regulation of energy balance and may also modulate blood pressure [
         <a href="#rid24">
          24
         </a>
         ]. As an example, the increase in sympathetic nerve activity induced by hyperinsulinemia can be diminished by antagonizing the melanocortin receptor [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4019259743">
         <span class="h3">
          Genetic susceptibility
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is substantial interindividual variability in the association of adiposity and blood pressure; hence, it is likely that an additional factor or factors modify the relationship of weight with blood pressure. One such factor is genetic susceptibility. Another possibility is that the effects of insulin on blood pressure may in part be mediated by other factors, such as the melanocortin pathway, as noted above.
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h1">
          WEIGHT REDUCTION TO LOWER BLOOD PRESSURE
         </span>
        </p>
        <p class="headingAnchor" id="H1960600792">
         <span class="h2">
          General approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         Weight loss can lower blood pressure and, along with other lifestyle interventions, is recommended in hypertensive patients who are overweight or obese [
         <a href="#rid26">
          26-29
         </a>
         ].
        </p>
        <p>
         Options for weight loss in hypertensive patients who are overweight or obese are similar to those in nonhypertensive patients. The approach to weight loss in such patients is presented elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/5371.html" rel="external">
          "Obesity in adults: Overview of management"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1240982760">
         <span class="h2">
          Effects of weight loss interventions on blood pressure
         </span>
        </p>
        <p class="headingAnchor" id="H3593793674">
         <span class="h3">
          Behavioral weight loss (lifestyle modification)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Behavioral weight loss programs primarily emphasize a reduction in calorie intake in order to achieve initial weight loss. Calorie reduction is more important than selecting a diet with a specific macronutrient composition (such as a low-fat or a low-carbohydrate diet) [
         <a href="#rid30">
          30,31
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5375.html" rel="external">
          "Obesity in adults: Dietary therapy", section on 'Our approach'
         </a>
         .)
        </p>
        <p>
         Increased physical activity is also important, particularly to maintain weight loss, once achieved [
         <a href="#rid32">
          32
         </a>
         ]. However, it is difficult to achieve and sustain calorie imbalance through physical activity alone. (See
         <a class="medical medical_review" href="/z/d/html/5382.html" rel="external">
          "Obesity in adults: Behavioral therapy"
         </a>
         .)
        </p>
        <p>
         Behavioral weight loss lowers blood pressure in nonhypertensive individuals (and thereby can prevent the development of hypertension). Weight loss also lowers blood pressure when used as initial therapy in hypertensive patients (before drugs are initiated), when used as a cointervention with other nondrug therapies that reduce blood pressure (such as sodium reduction), and when used in conjunction with antihypertensive drug therapy [
         <a href="#rid27">
          27,32
         </a>
         ]. Among those taking antihypertensive medications, behavioral weight loss can permit some patients to withdraw medication and still maintain blood pressure control.
        </p>
        <p>
         The magnitude of the effect of behavioral weight loss on blood pressures was examined in a systematic review of eight trials of hypertensive patients; the mean reduction in systolic/diastolic blood pressure was 4.5/3.2 mmHg [
         <a href="#rid33">
          33
         </a>
         ]. However, the reduction in blood pressure with weight loss is dose dependent (ie, greater weight loss produces a greater reduction in blood pressure)  (
         <a class="graphic graphic_figure graphicRef118106" href="/z/d/graphic/118106.html" rel="external">
          figure 4
         </a>
         ) [
         <a href="#rid30">
          30,32-34
         </a>
         ].
        </p>
        <p>
         There are a variety of approaches to behavioral weight loss, such as clinician-directed behavioral weight loss, commercial weight loss programs, internet-based programs, mobile phone apps, and wearable physical activity monitors. Our approach to behavioral weight loss is presented elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/5382.html" rel="external">
          "Obesity in adults: Behavioral therapy", section on 'Our approach'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4089325151">
         <span class="h3">
          Weight loss drugs
         </span>
         <span class="headingEndMark">
          —
         </span>
         Weight-reducing drugs have diverse effects on blood pressure, largely dependent on their mechanism of action [
         <a href="#rid35">
          35
         </a>
         ]. Many weight loss medications, particularly sympathomimetic amines, raise blood pressure despite a decrease in weight. However, some weight loss medications (eg,
         <a class="drug drug_general" data-topicid="10179" href="/z/d/drug information/10179.html" rel="external">
          orlistat
         </a>
         , which blocks fat absorption, and glucagon-like peptide-1 [GLP-1] agonists) can lower blood pressure. (See
         <a class="medical medical_review" href="/z/d/html/5376.html" rel="external">
          "Obesity in adults: Drug therapy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1698198572">
         <span class="h3">
          Weight loss surgery
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with marked obesity may require surgical therapy to produce and maintain an adequate degree of weight loss. (See
         <a class="medical medical_review" href="/z/d/html/5371.html" rel="external">
          "Obesity in adults: Overview of management"
         </a>
         .)
        </p>
        <p>
         Weight loss surgery (eg, Roux-en-Y gastric bypass) reduces blood pressure at one year, although the effect may not be significantly greater than lifestyle interventions alone [
         <a href="#rid36">
          36
         </a>
         ]. The fall in blood pressure with weight loss is accompanied by a decrease in arterial stiffness [
         <a href="#rid37">
          37
         </a>
         ].
        </p>
        <p>
         The long-term effects of weight loss surgery on blood pressure were examined in the Swedish Obese Subjects study [
         <a href="#rid28">
          28
         </a>
         ]. Bariatric surgery reduced blood pressure and controlled hypertension at two years compared with no surgery, but there were no differences in blood pressure at six to eight years.
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Long-term effects of weight reduction
         </span>
         <span class="headingEndMark">
          —
         </span>
         Contemporary behavioral weight loss programs, on average, achieve approximately 5 percent weight loss by six months. However, most people who lose weight regain some weight over time, possibly because of a persistence of hormonal adaptions to weight loss that reduce total and resting energy expenditure and promote weight  (
         <a class="graphic graphic_figure graphicRef63172" href="/z/d/graphic/63172.html" rel="external">
          figure 5
         </a>
         ). These observations suggest that strong mechanisms operate to maintain excess body weight and that weight regain is not merely a loss of motivation to reduce calorie intake and/or increase physical activity. (See
         <a class="medical medical_review" href="/z/d/html/5375.html" rel="external">
          "Obesity in adults: Dietary therapy", section on 'Maintaining weight loss'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5371.html" rel="external">
          "Obesity in adults: Overview of management", section on 'Maintenance of weight loss'
         </a>
         .)
        </p>
        <p>
         Long-term effects of weight loss on blood pressure likely depend upon the extent to which weight loss is sustained. In the Framingham Heart Study, the long-term effect of weight loss was evaluated among 623 overweight 30- to 49-year-olds and 604 overweight 50- to 65-year-olds over an eight-year period [
         <a href="#rid38">
          38
         </a>
         ]. Sustained weight loss of 6.8 kg or more was associated with a 22 and 26 percent reduction in relative risk of developing hypertension (defined as 140/90 mmHg) for the two groups, respectively. However, other studies in patients who had sustained weight loss found that, despite initial short-term declines in blood pressure, long-term blood pressure was not reduced [
         <a href="#rid28">
          28,39
         </a>
         ].
        </p>
        <p>
         The best available evidence suggests that an increase in physical activity should always be added to a reduced calorie intake in order to sustain weight loss [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h1">
          EFFECTS OF ANTIHYPERTENSIVE DRUGS ON WEIGHT AND WEIGHT LOSS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Antihypertensive agents are often necessary if patients cannot maintain a satisfactory blood pressure with lifestyle modification, including weight loss if appropriate. Recommendations for antihypertensive drug therapy in patients with hypertension are discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/3869.html" rel="external">
          "Choice of drug therapy in primary (essential) hypertension"
         </a>
         .)
        </p>
        <p>
         In general, beta blockers may make weight reduction more difficult. In the Trial of Antihypertensive Interventions and Management (TAIM), for example, the effect of caloric restriction on blood pressure was examined in 878 patients with hypertension treated with
         <a class="drug drug_general" data-topicid="8940" href="/z/d/drug information/8940.html" rel="external">
          atenolol
         </a>
         (50 mg/day),
         <a class="drug drug_general" data-topicid="9255" href="/z/d/drug information/9255.html" rel="external">
          chlorthalidone
         </a>
         (25 mg/day), or placebo [
         <a href="#rid41">
          41
         </a>
         ]. The mean weight reduction at six months was 3.0 kg among those treated with atenolol compared with 6.9 kg in those treated with chlorthalidone and 4.4 kg among those given placebo. These differences were attenuated but still present at 24 months. How beta blockers impair weight loss is unclear, although reduced sympathetic tone could diminish the basal metabolic rate and/or remove the normal inhibitory effect of catecholamines on appetite.
        </p>
        <p>
         However, if weight loss is attained, the blood pressure-lowering effect does not depend upon the class of antihypertensive medication taken [
         <a href="#rid42">
          42
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H524449919">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/109601.html" rel="external">
          "Society guideline links: Hypertension in adults"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/111344.html" rel="external">
          "Society guideline links: Obesity in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topic (see
         <a class="medical medical_basics" href="/z/d/html/16171.html" rel="external">
          "Patient education: Controlling your blood pressure through lifestyle (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topic (see
         <a class="medical medical_patient" href="/z/d/html/4415.html" rel="external">
          "Patient education: High blood pressure, diet, and weight (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H776720206">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Increased adiposity, whether assessed as higher body mass index (BMI), higher weight, larger waist circumference, or longitudinal weight gain, is strongly associated with higher blood pressure and development of hypertension  (
         <a class="graphic graphic_figure graphicRef76866" href="/z/d/graphic/76866.html" rel="external">
          figure 1
         </a>
         and
         <a class="graphic graphic_figure graphicRef52842" href="/z/d/graphic/52842.html" rel="external">
          figure 2
         </a>
         ). Excess body weight (including overweight and obesity) accounts for a larger attributable fraction of hypertension. (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Overweight and obesity may raise blood pressure through a variety of mechanisms, including renal injury, insulin resistance, sleep-disordered breathing, and increased sympathetic activity induced by the leptin-melanocortin pathway. (See
         <a class="local">
          'Pathogenesis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Weight loss can lower blood pressure and, along with other lifestyle interventions, is recommended in hypertensive patients who are overweight or obese  (
         <a class="graphic graphic_figure graphicRef118106" href="/z/d/graphic/118106.html" rel="external">
          figure 4
         </a>
         ). Options for weight loss in hypertensive patients who are overweight or obese (behavioral weight loss, weight loss medications, weight loss surgery) are similar to those in nonhypertensive patients. (See
         <a class="local">
          'Behavioral weight loss (lifestyle modification)'
         </a>
         above and
         <a class="local">
          'Weight loss drugs'
         </a>
         above and
         <a class="local">
          'Weight loss surgery'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/5371.html" rel="external">
          "Obesity in adults: Overview of management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beta blockers may make weight reduction more difficult to achieve. (See
         <a class="local">
          'Effects of antihypertensive drugs on weight and weight loss'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4195085546">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Norman M Kaplan, MD, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Appel LJ, Brands MW, Daniels SR, et al. Dietary approaches to prevent and treat hypertension: a scientific statement from the American Heart Association. Hypertension 2006; 47:296.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           GBD 2015 Obesity Collaborators, Afshin A, Forouzanfar MH, et al. Health Effects of Overweight and Obesity in 195 Countries over 25 Years. N Engl J Med 2017; 377:13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hall ME, Cohen JB, Ard JD, et al. Weight-Loss Strategies for Prevention and Treatment of Hypertension: A Scientific Statement From the American Heart Association. Hypertension 2021; 78:e38.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huang Z, Willett WC, Manson JE, et al. Body weight, weight change, and risk for hypertension in women. Ann Intern Med 1998; 128:81.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shihab HM, Meoni LA, Chu AY, et al. Body mass index and risk of incident hypertension over the life course: the Johns Hopkins Precursors Study. Circulation 2012; 126:2983.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Forman JP, Stampfer MJ, Curhan GC. Diet and lifestyle risk factors associated with incident hypertension in women. JAMA 2009; 302:401.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhao Y, Zhang M, Luo X, et al. Association of 6-year waist circumference gain and incident hypertension. Heart 2017; 103:1347.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilson PW, D'Agostino RB, Sullivan L, et al. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med 2002; 162:1867.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schmieder RE, Messerli FH. Does obesity influence early target organ damage in hypertensive patients? Circulation 1993; 87:1482.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ahmed SB, Fisher ND, Stevanovic R, Hollenberg NK. Body mass index and angiotensin-dependent control of the renal circulation in healthy humans. Hypertension 2005; 46:1316.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Unger RH. Reinventing type 2 diabetes: pathogenesis, treatment, and prevention. JAMA 2008; 299:1185.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sarzani R, Salvi F, Dessì-Fulgheri P, Rappelli A. Renin-angiotensin system, natriuretic peptides, obesity, metabolic syndrome, and hypertension: an integrated view in humans. J Hypertens 2008; 26:831.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hall JE, do Carmo JM, da Silva AA, et al. Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms. Circ Res 2015; 116:991.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rahmouni K, Correia ML, Haynes WG, Mark AL. Obesity-associated hypertension: new insights into mechanisms. Hypertension 2005; 45:9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities--the role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996; 334:374.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rocchini AP, Katch V, Kveselis D, et al. Insulin and renal sodium retention in obese adolescents. Hypertension 1989; 14:367.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Steinberg HO, Chaker H, Leaming R, et al. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest 1996; 97:2601.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nieto FJ, Young TB, Lind BK, et al. Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. Sleep Heart Health Study. JAMA 2000; 283:1829.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwartz AR, Patil SP, Laffan AM, et al. Obesity and obstructive sleep apnea: pathogenic mechanisms and therapeutic approaches. Proc Am Thorac Soc 2008; 5:185.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Senaratna CV, Perret JL, Lodge CJ, et al. Prevalence of obstructive sleep apnea in the general population: A systematic review. Sleep Med Rev 2017; 34:70.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Phillips BG, Narkiewicz K, Pesek CA, et al. Effects of obstructive sleep apnea on endothelin-1 and blood pressure. J Hypertens 1999; 17:61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goodfriend TL, Calhoun DA. Resistant hypertension, obesity, sleep apnea, and aldosterone: theory and therapy. Hypertension 2004; 43:518.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rahmouni K. Obesity, sympathetic overdrive, and hypertension: the leptin connection. Hypertension 2010; 55:844.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greenfield JR, Miller JW, Keogh JM, et al. Modulation of blood pressure by central melanocortinergic pathways. N Engl J Med 2009; 360:44.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ward KR, Bardgett JF, Wolfgang L, Stocker SD. Sympathetic response to insulin is mediated by melanocortin 3/4 receptors in the hypothalamic paraventricular nucleus. Hypertension 2011; 57:435.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 2018; 71:e13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Semlitsch T, Jeitler K, Berghold A, et al. Long-term effects of weight-reducing diets in people with hypertension. Cochrane Database Syst Rev 2016; 3:CD008274.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sjöström CD, Peltonen M, Wedel H, Sjöström L. Differentiated long-term effects of intentional weight loss on diabetes and hypertension. Hypertension 2000; 36:20.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Siebenhofer A, Jeitler K, Horvath K, et al. Long-term effects of weight-reducing drugs in people with hypertension. Cochrane Database Syst Rev 2016; 3:CD007654.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sacks FM, Bray GA, Carey VJ, et al. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. N Engl J Med 2009; 360:859.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tobias DK, Chen M, Manson JE, et al. Effect of low-fat diet interventions versus other diet interventions on long-term weight change in adults: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 2015; 3:968.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Whelton PK, Appel LJ, Espeland MA, et al. Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group. JAMA 1998; 279:839.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Semlitsch T, Krenn C, Jeitler K, et al. Long-term effects of weight-reducing diets in people with hypertension. Cochrane Database Syst Rev 2021; 2:CD008274.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stevens VJ, Obarzanek E, Cook NR, et al. Long-term weight loss and changes in blood pressure: results of the Trials of Hypertension Prevention, phase II. Ann Intern Med 2001; 134:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jin J. JAMA PATIENT PAGE. Specific Medications for Weight Loss. JAMA 2015; 314:742.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ikramuddin S, Korner J, Lee WJ, et al. Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: the Diabetes Surgery Study randomized clinical trial. JAMA 2013; 309:2240.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dengo AL, Dennis EA, Orr JS, et al. Arterial destiffening with weight loss in overweight and obese middle-aged and older adults. Hypertension 2010; 55:855.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moore LL, Visioni AJ, Qureshi MM, et al. Weight loss in overweight adults and the long-term risk of hypertension: the Framingham study. Arch Intern Med 2005; 165:1298.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laaksonen DE, Laitinen T, Schönberg J, et al. Weight loss and weight maintenance, ambulatory blood pressure and cardiac autonomic tone in obese persons with the metabolic syndrome. J Hypertens 2003; 21:371.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mozaffarian D, Hao T, Rimm EB, et al. Changes in diet and lifestyle and long-term weight gain in women and men. N Engl J Med 2011; 364:2392.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davis BR, Oberman A, Blaufox MD, et al. Effect of antihypertensive therapy on weight loss. The Trial of Antihypertensive Interventions and Management Research Group. Hypertension 1992; 19:393.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Espeland MA, Whelton PK, Kostis JB, et al. Predictors and mediators of successful long-term withdrawal from antihypertensive medications. TONE Cooperative Research Group. Trial of Nonpharmacologic Interventions in the Elderly. Arch Fam Med 1999; 8:228.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 3875 Version 33.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16434724" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Dietary approaches to prevent and treat hypertension: a scientific statement from the American Heart Association.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28604169" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Health Effects of Overweight and Obesity in 195 Countries over 25 Years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34538096" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Weight-Loss Strategies for Prevention and Treatment of Hypertension: A Scientific Statement From the American Heart Association.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9441586" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Body weight, weight change, and risk for hypertension in women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23151344" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Body mass index and risk of incident hypertension over the life course: the Johns Hopkins Precursors Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19622819" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Diet and lifestyle risk factors associated with incident hypertension in women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28389523" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Association of 6-year waist circumference gain and incident hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12196085" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Overweight and obesity as determinants of cardiovascular risk: the Framingham experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8491003" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Does obesity influence early target organ damage in hypertensive patients?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16286575" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Body mass index and angiotensin-dependent control of the renal circulation in healthy humans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18334695" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Reinventing type 2 diabetes: pathogenesis, treatment, and prevention.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18398321" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Renin-angiotensin system, natriuretic peptides, obesity, metabolic syndrome, and hypertension: an integrated view in humans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25767285" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15583075" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Obesity-associated hypertension: new insights into mechanisms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8538710" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Hypertension and associated metabolic abnormalities--the role of insulin resistance and the sympathoadrenal system.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2676858" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Insulin and renal sodium retention in obese adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8647954" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10770144" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. Sleep Heart Health Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18250211" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Obesity and obstructive sleep apnea: pathogenic mechanisms and therapeutic approaches.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27568340" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Prevalence of obstructive sleep apnea in the general population: A systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10100095" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Effects of obstructive sleep apnea on endothelin-1 and blood pressure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14732721" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Resistant hypertension, obesity, sleep apnea, and aldosterone: theory and therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20194295" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Obesity, sympathetic overdrive, and hypertension: the leptin connection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19092146" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Modulation of blood pressure by central melanocortinergic pathways.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21263116" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Sympathetic response to insulin is mediated by melanocortin 3/4 receptors in the hypothalamic paraventricular nucleus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29133356" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26934541" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Long-term effects of weight-reducing diets in people with hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10904007" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Differentiated long-term effects of intentional weight loss on diabetes and hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26934640" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Long-term effects of weight-reducing drugs in people with hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19246357" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26527511" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Effect of low-fat diet interventions versus other diet interventions on long-term weight change in adults: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9515998" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33555049" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Long-term effects of weight-reducing diets in people with hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11187414" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Long-term weight loss and changes in blood pressure: results of the Trials of Hypertension Prevention, phase II.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26284734" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : JAMA PATIENT PAGE. Specific Medications for Weight Loss.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23736733" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: the Diabetes Surgery Study randomized clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20212267" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Arterial destiffening with weight loss in overweight and obese middle-aged and older adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15956011" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Weight loss in overweight adults and the long-term risk of hypertension: the Framingham study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12569268" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Weight loss and weight maintenance, ambulatory blood pressure and cardiac autonomic tone in obese persons with the metabolic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21696306" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Changes in diet and lifestyle and long-term weight gain in women and men.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1555871" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Effect of antihypertensive therapy on weight loss. The Trial of Antihypertensive Interventions and Management Research Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10333818" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Predictors and mediators of successful long-term withdrawal from antihypertensive medications. TONE Cooperative Research Group. Trial of Nonpharmacologic Interventions in the Elderly.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
